Volume 13 Issue 4
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2022  >  13(4): 516-521
Xu Yu, Lian Qiaoyan, Chen Ao, et al. Protein A immunoadsorption in the treatment of de novo DSA-mediated acute rejection after lung transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(4): 516-521. doi: 10.3969/j.issn.1674-7445.2022.04.016
Citation: Xu Yu, Lian Qiaoyan, Chen Ao, et al. Protein A immunoadsorption in the treatment of de novo DSA-mediated acute rejection after lung transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(4): 516-521. doi: 10.3969/j.issn.1674-7445.2022.04.016
shu

Protein A immunoadsorption in the treatment of de novo DSA-mediated acute rejection after lung transplantation

doi: 10.3969/j.issn.1674-7445.2022.04.016

  • The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, Guangzhou 510012, China

More Information
  • Corresponding author: Ju Chunrong, Email: juchunrong@126.com
  • Received Date: 2022-03-23
    Available Online: 2022-07-14
  • Publish Date: 2022-07-15
    Abstract
  •   Objective  To investigate the treatment on de novo donor specific antibody (dnDSA) mediated acute rejection after lung transplantation.  Methods  Clinical data of 1 recipient with antibody-mediated rejection (AMR) early after lung transplantation was retrospectively analyzed. The process of diagnosis and treatment were assessed.  Results  The recipient underwent right lung transplantation due to systemic sclerosis-associated end-stage interstitial lung disease. Preoperatively, classⅠ panel reactive antibody (PRA) was positive (11%). No pretreatment was given before transplantation. Antithymocyte globulin induction therapy was delivered on the day of transplantation and postoperatively. The recipient was properly recovered early after transplantation. Chest tightness and shortness of breath occurred at postoperative 13 d, which were progressively worsened and rapidly progressed into type Ⅰ respiratory failure. Class Ⅰ PRA was increased to 58%, and dnDSA was observed at the loci of A24: 02. The mean fluorescence intensity (MFI) was 2 110. According to the guidelines of International Society for Heart and Lung Transplantation, the recipient was diagnosed as possible AMR. After comprehensive treatment including plasmapheresis, protein A immunoadsorption, glucocorticoid pulse, rituximab and immunoglobulin intravenous drip, the PRA and DSA levels were gradually decreased, and the MFI of DSA was 0 at postoperative 20 d. Clinical condition of the recipient was gradually improved. The dyspnea was healed, shortness of breath was eased, respiratory failure was treated, and pulmonary effusion was gradually absorbed. At postoperative 45 d, the recipient was discharged after full recovery. During 1-year follow-up, the recipient was physically stable and obtained normal quality of life. Class Ⅰ PRA was 5%, and class Ⅱ PRA was negative. No DSA was noted.  Conclusions  Based on traditional drug therapy, supplement of protein A immunoadsorption therapy may effectively eliminate DSA from the circulating blood of the recipient and mitigate the damage of target organs. Ideal short- and long-term prognosis may be achieved. Traditional drug therapy combined with immunoadsorption may yield ideal efficacy in treating AMR after lung transplantation.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    GREER M, WERLEIN C, JONIGK D. Surveillance for acute cellular rejection after lung transplantation[J]. Ann Transl Med, 2020, 8(6): 410. DOI: 10.21037/atm.2020.02.127.
    [2]
    郭晖. 移植肺病理学诊断标准及其进展[J]. 器官移植, 2022, 13(1): 19-31. DOI: 10.3969/j.issn.1674-7445.2022.01.004.

    GUO H. Diagnostic criteria and research progress on lung allograft pathology[J]. Organ Transplant, 2022, 13(1): 19-31. DOI: 10.3969/j.issn.1674-7445.2022.01.004.
    [3]
    SUBRAMANI MV, PANDIT S, GADRE SK. Acute rejection and post lung transplant surveillance[J]. Indian J Thorac Cardiovasc Surg, 2022, DOI: 10.1007/s12055-021-01320-z[Epubaheadofprint].
    [4]
    OHM B, JUNGRAITHMAYR W. B cell immunity in lung transplant rejection - effector mechanisms and therapeutic implications[J]. Front Immunol, 2022, 13: 845867. DOI: 10.3389/fimmu.2022.845867..
    [5]
    PARULEKAR AD, KAO CC. Detection, classification, and management of rejection after lung transplantation[J]. J Thorac Dis, 2019, 11(Suppl 14): S1732-S1739. DOI: 10.21037/jtd.2019.03.83.
    [6]
    YOUNG KA, ALI HA, BEERMANN KJ, et al. Lung Transplantation and the era of the sensitized patient[J]. Front Immunol, 2021, 12: 689420. DOI: 10.3389/fimmu.2021.689420.
    [7]
    WITT CA, GAUT JP, YUSEN RD, et al. Acute antibody-mediated rejection after lung transplantation[J]. J Heart Lung Transplant, 2013, 32(10): 1034-1040. DOI: 10.1016/j.healun.2013.07.004.
    [8]
    BRUGIÈRE O, SUBERBIELLE C, THABUT G, et al. Lung transplantation in patients with pretransplantation donor-specific antibodies detected by Luminex assay[J]. Transplantation, 2013, 95(5): 761-765. DOI: 10.1097/TP.0b013e31827afb0f.
    [9]
    BERY AI, HACHEM RR. Antibody-mediated rejection after lung transplantation[J]. Ann Transl Med, 2020, 8(6): 411. DOI: 10.21037/atm.2019.11.86.
    [10]
    DEL ANGEL-PABLO AD, BUENDÍA-ROLDÁN I, MEJÍA M, et al. Anti-HLA class Ⅱ antibodies correlate with C-reactive protein levels in patients with rheumatoid arthritis associated with interstitial lung disease[J]. Cells, 2020, 9(3): 691. DOI: 10.3390/cells9030691.
    [11]
    GOCHI F, CHEN-YOSHIKAWA TF, KAYAWAKE H, et al. Comparison of de novo donor-specific antibodies between living and cadaveric lung transplantation[J]. J Heart Lung Transplant, 2021, 40(7): 607-613. DOI: 10.1016/j.healun.2021.03.019.
    [12]
    HOGEN R, DINORCIA J, DHANIREDDY K. Antibody-mediated rejection: what is the clinical relevance?[J]. Curr Opin Organ Transplant, 2017, 22(2): 97-104. DOI: 10.1097/MOT.0000000000000391.
    [13]
    TIKKANEN JM, SINGER LG, KIM SJ, et al. De novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation[J]. Am J Respir Crit Care Med, 2016, 194(5): 596-606. DOI: 10.1164/rccm.201509-1857OC.
    [14]
    LEVINE DJ, GLANVILLE AR, ABOYOUN C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation[J]. J Heart Lung Transplant, 2016, 35(4): 397-406. DOI: 10.1016/j.healun.2016.01.1223.
    [15]
    SIS B. Endothelial molecules decipher the mechanisms and functional pathways in antibody-mediated rejection[J]. Hum Immunol, 2012, 73(12): 1218-1225. DOI: 10.1016/j.humimm.2012.07.332.
    [16]
    TSAI EW, REED EF. MHC class I signaling: new functional perspectives for an old molecule[J]. Tissue Antigens, 2014, 83(6): 375-381. DOI: 10.1111/tan.12381.
    [17]
    VALENZUELA NM, MCNAMARA JT, REED EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms[J]. Curr Opin Organ Transplant, 2014, 19(1): 33-40. DOI: 10.1097/MOT.0000000000000040.
    [18]
    ROUX A, LEVINE DJ, ZEEVI A, et al. Banff lung report: current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR)[J]. Am J Transplant, 2019, 19(1): 21-31. DOI: 10.1111/ajt.14990.
    [19]
    HULBERT AL, PAVLISKO EN, PALMER SM. Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation[J]. Curr Opin Organ Transplant, 2018, 23(3): 308-315. DOI: 10.1097/MOT.0000000000000537.
    [20]
    HALVERSON LP, HACHEM RR. Antibody-mediated rejection and lung transplantation[J]. Semin Respir Crit Care Med, 2021, 42(3): 428-435. DOI: 10.1055/s-0041-1728796.
    [21]
    HACHEM RR, YUSEN RD, MEYERS BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation[J]. J Heart Lung Transplant, 2010, 29(9): 973-980. DOI: 10.1016/j.healun.2010.05.006.
    [22]
    NEUHAUS K, HOHLFELDER B, BOLLINGER J, et al. Antibody-mediated rejection management following lung transplantation[J]. Ann Pharmacother, 2022, 56(1): 60-64. DOI: 10.1177/10600280211012410.
    [23]
    PHAM C, PIERCE BJ, NGUYEN DT, et al. Assessment of carfilzomib treatment response in lung transplant recipients with antibody-mediated rejection[J]. Transplant Direct, 2021, 7(4): e680. DOI: 10.1097/TXD.0000000000001131.
    [24]
    MULLER YD, AUBERT JD, VIONNET J, et al. Acute antibody-mediated rejection 1 week after lung transplantation successfully treated with eculizumab, intravenous immunoglobulins, and rituximab[J]. Transplantation, 2018, 102(6): e301-e303. DOI: 10.1097/TP.0000000000002165.
    [25]
    TIMOFEEVA OA, CHOE J, ALSAMMAK M, et al. Guiding therapeutic plasma exchange for antibody-mediated rejection treatment in lung transplant recipients - a retrospective study[J]. Transpl Int, 2021, 34(4): 700-708. DOI: 10.1111/tri.13825.
    [26]
    KÄLBLE F, SÜSAL C, PEGO DA SILVA L, et al. Living donor kidney transplantation in patients with donor-specific HLA antibodies after desensitization with immunoadsorption[J]. Front Med (Lausanne), 2021, 8: 781491. DOI: 10.3389/fmed.2021.781491.
    [27]
    KULKARNI HS, BEMISS BC, HACHEM RR. Antibody-mediated rejection in lung transplantation[J]. Curr Transplant Rep, 2015, 2(4): 316-323. DOI: 10.1007/s40472-015-0074-5.
    [28]
    SWEET SC, ARMSTRONG B, BLATTER J, et al. CTOTC-08: a multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients[J]. Am J Transplant, 2022, 22(1): 230-244. DOI: 10.1111/ajt.16862.
    [29]
    BÖHMIG GA, REGELE H, EXNER M, et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption[J]. J Am Soc Nephrol, 2001, 12(11): 2482-2489. DOI: 10.1681/ASN.V12112482.
    [30]
    FUCHS K, RUMMLER S, RIES W, et al. Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications[J]. Ther Apher Dial, 2022, 26(1): 229-241. DOI: 10.1111/1744-9987.13663.
    [31]
    姬芳玲, 吴健, 贾凌云. 免疫吸附治疗自身免疫疾病的研究进展[J]. 生物化学与生物物理进展, 2022, 49(1): 139-148. DOI: 10.16476/j.pibb.2021.0384.

    JI FL, WU J, JIA LY. Research progress of immunoadsorption in the treatment of autoimmune diseases: a review[J]. Prog Biochem Biophys, 2022, 49(1): 139-148. DOI: 10.16476/j.pibb.2021.0384.
    [32]
    张政, 蒙兴文, 钟小凤, 等. 免疫吸附治疗类风湿关节炎的应用综述[J]. 当代医学, 2021, 27(25): 193-194. DOI: 10.3969/j.issn.1009-4393.2021.25.085.

    ZHANG Z, MENG XW, ZHONG XF, et al. A review of the application of immunosorbent in the treatment of rheumatoid arthritis[J]. Contemp Med, 2021, 27(25): 193-194. DOI: 10.3969/j.issn.1009-4393.2021.25.085.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (332) PDF downloads(80) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return